

Special Issue

Metabolic Disorders in Pregnancy: From (Epi)genetics to Functional Consequences 2.0

Message from the Guest Editors

Metabolic disorders in pregnancy are a growing health problem worldwide. The global epidemic of obesity is leading to an increased number of women who enter pregnancy with excessive body fat, predisposing them to pregnancy-related metabolic conditions such as gestational diabetes mellitus (GDM). Both maternal obesity and GDM are associated with serious short-term and long-term adverse consequences for mother and child. The aim of this Special Issue is to gather the latest studies that deepen our current understanding of the pathophysiological mechanisms involved in metabolic disorders in pregnancy, with a focus on maternal obesity and GDM. We are particularly interested in studies of genetic and epigenetic factors, their interactions, functional consequences at the molecular, cellular, and whole organism levels, and potential utility as diagnostic or prognostic biomarkers. Studies on the influence of fetal sex and the role of the placenta are also appreciated. Both original research articles and reviews are of interest.

Guest Editors

Dr. Jasminka Štefulj

Department of Molecular Biology, Ruđer Bošković Institute, Zagreb, Croatia

Prof. Dr. Gernot Desoye

Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria

Deadline for manuscript submissions

closed (15 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/137089

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).